Increased serum nesfatin-1 levels in patients with acromegaly

Nesfatin-1 was identified as a satiety factor involved in the regulation of metabolism. Altered levels of circulating nesfatin-1 had been observed in a variety of diseases characterized by energy imbalance. However, there was no published data about nesfatin-1 levels in acromegaly.We evaluated serum...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2020-10, Vol.99 (40), p.e22432-e22432
Main Authors: Yang, Yakun, Han, Song, Yang, Zuocheng, Wang, Pengfei, Yan, Chang-Xiang, Liu, Ning
Format: Article
Language:English
Subjects:
Acromegaly - blood
Adenoma - blood
Adenoma - pathology
Adenoma - surgery
Adult
Blood Pressure
Case-Control Studies
Female
Human Growth Hormone - blood
Humans
Male
Middle Aged
Nucleobindins - blood
Observational Study
Pituitary Neoplasms - blood
Pituitary Neoplasms - pathology
Pituitary Neoplasms - surgery
ROC Curve
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nesfatin-1 was identified as a satiety factor involved in the regulation of metabolism. Altered levels of circulating nesfatin-1 had been observed in a variety of diseases characterized by energy imbalance. However, there was no published data about nesfatin-1 levels in acromegaly.We evaluated serum nesfatin-1 levels in 13 patients with acromegaly at baseline and postoperatively, and in 21 age- and body mass index (BMI)-matched healthy subjects.Compared with the healthy subjects, patients with acromegaly had significantly increased levels of serum insulin, high-density lipoprotein cholesterol, triglyceride, and growth hormone (GH). Moreover, the acromegaly group had nesfatin-1 levels higher than controls (1.96 ± 0.56 ng/mL vs 0.61 ± 0.10 ng/mL, P = .004). There was a positive correlation of serum nesfatin-1 levels with diastolic blood pressure (r = 0.579, P = .038) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.598, P = .031) in patients with acromegaly. While a successful surgery decreased serum GH levels, the serum nesfatin-1 levels did not change in acromegaly (P = .965). At last, we compared serum GH/nesfatin-1 levels with predictive markers for aggressive behaviors in pituitary adenomas. There was no relationship between serum nesfatin-1 levels and tumor's size, Ki-67 index, mutant p53, or MGMT proteins. However, increased serum GH levels were positively correlated with tumors' size (P = .023) and mutant p53 proteins expression (P = .028).Circulating nesfatin-1 was increased in acromegaly, which was involved in metabolism regulation.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000022432